Report date: July 15, 2026 (before market open) | Current price: ~$427 | Market cap: ~$83B
ELV shares have run hard into this print — from roughly $299 right before the Q1 report (April 22) to roughly $427 today, a ~43% rally in under three months, with the stock making fresh highs as recently as this week. That momentum reflects a very strong Q1 (adjusted EPS of $12.58, beating expectations) and a subsequent full-year guidance raise. The bar for tomorrow's print is therefore higher than it was three months ago, and any disappointment — particularly around the individual ACA book or Medicaid trend — is likely to be punished more than usual given how much good news is already in the price.
Consensus for Q2 2026 sits at roughly $6.15–$6.21 adjusted EPS on revenue of ~$48.5–$48.8 billion, which would be a year-over-year EPS decline (the prior-year quarter included favorable items), consistent with management's own guidance that Q2 EPS should equal about 23% of the revised full-year outlook of at least $26.75. The Street also models a benefit expense ratio near 89.4%, up from 86.8% in Q1 and above last year's Q2 level, reflecting normal seasonal claims patterns plus continued cost pressure in Medicaid. Analyst sentiment remains constructive (a "Moderate Buy" skew), but estimates have drifted slightly lower over the past 60 days rather than higher — a sign that the Q1 beat was viewed as partly seasonal/one-time rather than a clean trend improvement.
Full-year guidance and 2027 bridge. Management raised 2026 adjusted EPS guidance to at least $26.75, but flagged that roughly $1.00 of the Q1 beat came from non-recurring investment income, putting the "clean" 2026 baseline at $25.75, off of which the company reiterated confidence in at least 12% adjusted EPS growth in 2027. Watch for any language that either firms up or walks back that 2027 framing — it's the single biggest driver of the stock's forward multiple.
The CMS risk-adjustment matter — deadline lands right after earnings. Elevance took a $935 million accrual in Q1 tied to a February CMS notice regarding historical Medicare Advantage risk-adjustment data submissions (covering 2015–April 2023). The compliance deadline for remediation — after being pushed from March 30 to May 30 — now sits at July 31, 2026, just two weeks after this earnings call. Investors will want an update on whether the accrual still looks adequate, whether sanctions are still expected to be avoided, and any incremental cash/timing implications.
Medicaid — still the "trough year." Management has been explicit that 2026 is intended to be the low point for Medicaid margins (guided to roughly -1.75% operating margin), pressured by continued high-single-digit membership declines from eligibility redeterminations and a rate-to-trend gap that state negotiations are only gradually closing. Q2 commentary on redetermination pace, acuity mix in the remaining risk pool, and progress on state rate discussions will be important for confidence in a 2027 recovery.
Medicare Advantage — the one bright spot getting brighter. Portfolio repositioning (product changes, selective market exits) has MA tracking toward at least a 2% operating margin in 2026, and CMS's 2027 final rate notice was viewed as constructive. This dovetails with a broader sector signal: Wells Fargo just upgraded Humana to Overweight citing moderating MA cost trends and reduced earnings risk — a read-through that should be positive for ELV's own MA trajectory, though bid discipline for 2027 remains a live topic.
Individual ACA — the biggest swing factor into this print. This is arguably the most important debate heading into tomorrow. In Q1, Elevance saw a pronounced shift toward bronze-tier plans and guided that it was running ~1.2 million members ahead of plan for individual ACA by mid-year, while stopping short of raising full-year membership guidance given uncertainty about mix and morbidity. The read-through risk just got louder: HCA Healthcare pre-announced Tuesday and cut full-year guidance specifically because of a payer-mix shift toward uninsured patients as people lost ACA exchange coverage, revising its expected 2026 exchange-related earnings headwind up to $1.0–$1.2 billion from $600–900 million previously. That is a direct consequence of the enhanced ACA premium tax credits expiring at the end of 2025, which sharply raised net premiums for exchange enrollees. For ELV, the open questions are: (1) is the "healthier" bronze-plan enrollee mix holding up, or is adverse selection showing up faster than priced; (2) is retention/lapsation tracking as management described (worse-than-expected attrition concentrated among healthier, non-paying members, which is actually favorable to remaining risk-pool morbidity); and (3) does deferred cost-seasonality in bronze plans (more costs shifted to H2) show up as expected. A miss here would be the single most damaging outcome for the stock given the ACA book's outsized contribution to the recent guidance raise.
Carelon — margin timing, not a growth problem. Carelon's Q1 operating gain declined modestly on lower affiliated health-plan membership and continued investment in risk-based programs (oncology, post-acute, behavioral health), with CarelonRx tracking to a mid-5% margin for the year. Management framed this as normal mix/timing rather than a change in the long-term thesis, but investors will watch for confirmation that margin trajectory is still intact.
Capital return and balance sheet. ELV bought back $1.1 billion of stock in Q1 (average price ~$300, now well below the current ~$427 share price) and remains on track for at least $2.3 billion in buybacks for 2026, with full-year operating cash flow guided to at least $5.5 billion. Days-in-claims-payable rose to 46.6 days in Q1 (seasonal), and any commentary on reserve conservatism will matter given the size of the ACA and Medicaid uncertainties above.
Managed care earnings season is arriving with a mixed tone: HCA's warning is a fresh red flag specifically tied to ACA subsidy expiration and coverage losses, while Humana's upgrade suggests MA cost trends are moderating industry-wide. UNH reports the day after ELV (July 16), with sentiment there having improved under new CEO Stephen Hemsley's repricing/turnaround push — meaning ELV's print will be read partly as an early tell for the whole sector, not just a company-specific event.
Given the stock's sharp run-up into the print, even an in-line quarter with cautious ACA commentary could trigger profit-taking, while a clean beat-and-raise — especially with reassurance on the CMS matter and ACA risk pool — could extend the rally further.